| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $151.4M | +19.2% |
| SG&A Expense | $40.0M | +25.6% |
| Operating Income | -$191.4M | -20.5% |
| Pre-tax Income | -$167.8M | -25.4% |
| Income Tax | $4K | — |
| Net Income | -$167.8M | -25.4% |
| EPS (Basic) | -$1.63 | -12.4% |
| EPS (Diluted) | -$1.63 | -12.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $61.1M | +46.8% |
| Current Assets | $543.4M | +14.3% |
| Total Assets | $552.6M | +13.5% |
| Current Liabilities | $27.4M | +14.7% |
| Total Liabilities | $30.3M | +9.9% |
| Stockholders' Equity | $522.3M | +13.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$143.8M | -31.9% |
| Capital Expenditures | $256K | -80.5% |
| Investing Cash Flow | -$32.8M | +82.2% |
| Financing Cash Flow | $196.1M | -21.3% |
| Free Cash Flow | -$144.1M | -30.6% |